Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Rodríguez González, Raquel ^a   Sobrino, Tomás ^a   Rodríguez Yáñez, Manuel ^a   Millán, Mónica ^b   Brea, David ^a   Miranda, Elena ^c   Moldes, Octavio ^a   Pérez, Juan ^d   Lomas, David A ^c   Leira, Rogelio ^a   Dávalos, Antoni ^b   Castillo, José ^a  

^a Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; GELATINASE B; GLUTAMIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; NEUROSERPIN; BIOLOGICAL MARKER; NEUROPEPTIDE; SERINE PROTEINASE INHIBITOR;

AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE MARKER; EXCITOTOXICITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANKIN SCALE; RECEIVER OPERATING CHARACTERISTIC; BLOOD; BRAIN; PATHOLOGY; RISK; STROKE; TIME;

AGED; BIOLOGICAL MARKERS; BRAIN; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; NEUROPEPTIDES; ODDS RATIO; SERPINS; STROKE; TIME FACTORS;

EID: 79955757104     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-58     Document Type: Article

References (40)

1. Rogove AD, Siao C, Keyt B, Strickland S, Tsirka SE. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 1999, 112:4007-4016.
2. Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005, 93:655-660.
3. Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN, Osterwalder T, Rulicke T, Sonderegger P. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci 2001, 18:443-457.
4. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000, 96:569-576.
5. Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002, 106:740-745.
6. Rodríguez-González R, Millán M, Sobrino T, Miranda E, Brea D, Pérez de la Ossa N, Blanco M, Pérez J, Dorado L, Castellanos M, Lomas DA, Moro MA, Dávalos A, Castillo J. The natural tissue plasminogen activator inhibitor neuroserpin and acute ischemic stroke outcome. Thromb Haemost 2011, 105:421-429.
7. European Stroke Organisation (ESO) Executive Committee ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008, 25:457-507. European Stroke Organisation (ESO) Executive Committee.
8. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke 1993, 24:35-41.
9. Miranda E, MacLeod I, Davies MJ, Perez J, Romisch K, Crowther DC, Lomas DA. The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet 2008, 17:1527-1539.
10. Miranda E, Romisch K, Lomas DA. Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem 2004, 279:28283-28291.
11. Castillo J, Davalos A, Naveiro J, Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996, 27:1060-1065.
12. Castillo J, Davalos A, Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 1997, 349:79-83.
13. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, Tarkowski A. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol 1997, 110:492-499.
14. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31:2325-2329.
15. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107:598-603.
16. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004, 35:1671-1676.
17. Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Davalos A. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005, 36:1921-1926.
18. Castellanos M, Sobrino T, Millan M, Garcia M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Castillo J, Davalos A. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study. Stroke 2007, 38:1855-1859.
19. Castellanos M, Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis 2007, 24(Suppl 1):7-15.
20. Castellanos M, Castillo J, Davalos A. Laboratory studies in the investigation of stroke. Handb Clin Neurol 2008, 94:1081-1095.
21. Zhao G, Reynolds JN, Flavin MP. Temporal profile of tissue plasminogen activator (tpa) and inhibitor expression after transient focal cerebral ischemia. Neuroreport 2003, 14:1689-1692.
22. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001, 7:59-64.
23. Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, Rossier J, Jarrige AC, Mackenzie ET, Colloc'h N, Ali C, Vivien D. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of n-methyl-d-aspartate receptor signaling. J Biol Chem 2004, 279:50850-50856.
24. Lebeurrier N, Liot G, Lopez-Atalaya JP, Orset C, Fernandez-Monreal M, Sonderegger P, Ali C, Vivien D. The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol Cell Neurosci 2005, 30:552-558.
25. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A. Inflammation-mediated damage in progressing lacunar infarctions: A potential therapeutic target. Stroke 2002, 33:982-987.
26. Siao CJ, Fernandez SR, Tsirka SE. Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci 2003, 23:3234-3242.
27. Flavin MP, Zhao G, Ho LT. Microglial tissue plasminogen activator (tpa) triggers neuronal apoptosis in vitro. Glia 2000, 29:347-354.
28. Meager A. Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev 1999, 10:27-39.
29. Milner R, Campbell IL. The extracellular matrix and cytokines regulate microglial integrin expression and activation. J Immunol 2003, 170:3850-3858.
30. del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, Koziol JA. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007, 38:646-651.
31. Summers L, Kielty C, Pinteaux E. Adhesion to fibronectin regulates interleukin-1 beta expression in microglial cells. Mol Cell Neurosci 2009, 41:148-155.
32. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase b: A tuner and amplifier of immune functions. Trends Immunol 2001, 22:571-579.
33. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase a (mmp-2) and gelatinase b (mmp-9) activities in human brain after focal ischemia. Neurosci Lett 1997, 238:53-56.
34. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999, 19:624-633.
35. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998, 29:1020-1030.
36. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003, 34:40-46.
37. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003, 9:1313-1317.
38. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J, Lo EH. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005, 36:1954-1959.
39. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 2006, 66:1550-1555.
40. Rodríguez-González R, Agulla J, Sobrino T, Castillo J. Neuroprotective effect of neuroserpin in rat primary cortical cultures after oxygen and glucose deprivation and tPA. Neurochem Int 2011, 58:337-343.